Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2958291rdf:typepubmed:Citationlld:pubmed
pubmed-article:2958291lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:2958291lifeskim:mentionsumls-concept:C0020179lld:lifeskim
pubmed-article:2958291lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:2958291lifeskim:mentionsumls-concept:C0442027lld:lifeskim
pubmed-article:2958291lifeskim:mentionsumls-concept:C0040180lld:lifeskim
pubmed-article:2958291lifeskim:mentionsumls-concept:C0178602lld:lifeskim
pubmed-article:2958291lifeskim:mentionsumls-concept:C0205171lld:lifeskim
pubmed-article:2958291pubmed:issue6lld:pubmed
pubmed-article:2958291pubmed:dateCreated1987-11-17lld:pubmed
pubmed-article:2958291pubmed:abstractTextThe pharmacokinetic properties of a single oral dose of 100 mg of tiapride were studied in six patients with Huntington's disease. The results for five patients were consistent with a two compartment open model. Peak plasma concentrations were observed within 2 h following drug administration with a mean value of 0.92 micrograms/ml being recorded. The drug was rapidly eliminated as unmetabolised tiapride in the urine, 51% of the dose was recovered in 24 h. The plasma elimination half-life was 5.3 h and the average apparent plasma clearance was 16.6 l/h.lld:pubmed
pubmed-article:2958291pubmed:languageenglld:pubmed
pubmed-article:2958291pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2958291pubmed:citationSubsetIMlld:pubmed
pubmed-article:2958291pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2958291pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2958291pubmed:statusMEDLINElld:pubmed
pubmed-article:2958291pubmed:issn0031-6970lld:pubmed
pubmed-article:2958291pubmed:authorpubmed-author:NormanTTlld:pubmed
pubmed-article:2958291pubmed:authorpubmed-author:ChiuEElld:pubmed
pubmed-article:2958291pubmed:authorpubmed-author:JamesR HRHlld:pubmed
pubmed-article:2958291pubmed:authorpubmed-author:GregoryM SMSlld:pubmed
pubmed-article:2958291pubmed:issnTypePrintlld:pubmed
pubmed-article:2958291pubmed:volume32lld:pubmed
pubmed-article:2958291pubmed:ownerNLMlld:pubmed
pubmed-article:2958291pubmed:authorsCompleteYlld:pubmed
pubmed-article:2958291pubmed:pagination583-6lld:pubmed
pubmed-article:2958291pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:2958291pubmed:meshHeadingpubmed-meshheading:2958291-...lld:pubmed
pubmed-article:2958291pubmed:meshHeadingpubmed-meshheading:2958291-...lld:pubmed
pubmed-article:2958291pubmed:meshHeadingpubmed-meshheading:2958291-...lld:pubmed
pubmed-article:2958291pubmed:meshHeadingpubmed-meshheading:2958291-...lld:pubmed
pubmed-article:2958291pubmed:meshHeadingpubmed-meshheading:2958291-...lld:pubmed
pubmed-article:2958291pubmed:meshHeadingpubmed-meshheading:2958291-...lld:pubmed
pubmed-article:2958291pubmed:meshHeadingpubmed-meshheading:2958291-...lld:pubmed
pubmed-article:2958291pubmed:meshHeadingpubmed-meshheading:2958291-...lld:pubmed
pubmed-article:2958291pubmed:meshHeadingpubmed-meshheading:2958291-...lld:pubmed
pubmed-article:2958291pubmed:meshHeadingpubmed-meshheading:2958291-...lld:pubmed
pubmed-article:2958291pubmed:meshHeadingpubmed-meshheading:2958291-...lld:pubmed
pubmed-article:2958291pubmed:meshHeadingpubmed-meshheading:2958291-...lld:pubmed
pubmed-article:2958291pubmed:year1987lld:pubmed
pubmed-article:2958291pubmed:articleTitleSingle oral dose pharmacokinetics of tiapride in patients with Huntington's disease.lld:pubmed
pubmed-article:2958291pubmed:affiliationDepartment of Psychiatry, University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australia.lld:pubmed
pubmed-article:2958291pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2958291pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed